148 related articles for article (PubMed ID: 12171885)
1. Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas.
Shimamura T; Sakamoto M; Ino Y; Shimada K; Kosuge T; Sato Y; Tanaka K; Sekihara H; Hirohashi S
Clin Cancer Res; 2002 Aug; 8(8):2570-5. PubMed ID: 12171885
[TBL] [Abstract][Full Text] [Related]
2. Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma.
Liang JJ; Wang H; Rashid A; Tan TH; Hwang RF; Hamilton SR; Abbruzzese JL; Evans DB; Wang H
Clin Cancer Res; 2008 Nov; 14(21):7043-9. PubMed ID: 18981001
[TBL] [Abstract][Full Text] [Related]
3. RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis.
Masui T; Doi R; Koshiba T; Fujimoto K; Tsuji S; Nakajima S; Koizumi M; Toyoda E; Tulachan S; Ito D; Kami K; Mori T; Wada M; Noda M; Imamura M
Clin Cancer Res; 2003 May; 9(5):1779-84. PubMed ID: 12738734
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma.
Nitori N; Ino Y; Nakanishi Y; Yamada T; Honda K; Yanagihara K; Kosuge T; Kanai Y; Kitajima M; Hirohashi S
Clin Cancer Res; 2005 Apr; 11(7):2531-9. PubMed ID: 15814630
[TBL] [Abstract][Full Text] [Related]
5. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer.
Irie A; Yamauchi A; Kontani K; Kihara M; Liu D; Shirato Y; Seki M; Nishi N; Nakamura T; Yokomise H; Hirashima M
Clin Cancer Res; 2005 Apr; 11(8):2962-8. PubMed ID: 15837748
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of immunohistochemical RhoA expression on survival in pancreatic ductal adenocarcinoma: a high-throughput analysis.
Dittert DD; Kielisch C; Alldinger I; Zietz C; Meyer W; Dobrowolski F; Saeger HD; Baretton GB
Hum Pathol; 2008 Jul; 39(7):1002-10. PubMed ID: 18495213
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer.
Yamasawa K; Nio Y; Dong M; Yamaguchi K; Itakura M
Clin Cancer Res; 2002 Aug; 8(8):2563-9. PubMed ID: 12171884
[TBL] [Abstract][Full Text] [Related]
8. Survival and prognosis of invasive intraductal papillary mucinous neoplasms of the pancreas: comparison with pancreatic ductal adenocarcinoma.
Woo SM; Ryu JK; Lee SH; Yoo JW; Park JK; Kim YT; Yoon YB
Pancreas; 2008 Jan; 36(1):50-5. PubMed ID: 18192881
[TBL] [Abstract][Full Text] [Related]
9. Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis.
Sun HC; Qiu ZJ; Liu J; Sun J; Jiang T; Huang KJ; Yao M; Huang C
Int J Oncol; 2007 Jun; 30(6):1359-67. PubMed ID: 17487356
[TBL] [Abstract][Full Text] [Related]
10. Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma.
Uehara H; Miyamoto M; Kato K; Ebihara Y; Kaneko H; Hashimoto H; Murakami Y; Hase R; Takahashi R; Mega S; Shichinohe T; Kawarada Y; Itoh T; Okushiba S; Kondo S; Katoh H
Cancer Res; 2004 May; 64(10):3533-7. PubMed ID: 15150108
[TBL] [Abstract][Full Text] [Related]
11. Prognostic role of angiogenesis and its correlations with thymidine phosphorylase and p53 expression in ductal adenocarcinoma of the pancreas.
Jinfeng M; Kimura W; Sakurai F; Moriya T; Mizutani M; Hirai I
Hepatogastroenterology; 2007 Sep; 54(78):1635-40. PubMed ID: 18019682
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times.
Kristiansen G; Jacob J; Buckendahl AC; Grützmann R; Alldinger I; Sipos B; Klöppel G; Bahra M; Langrehr JM; Neuhaus P; Dietel M; Pilarsky C
Clin Cancer Res; 2006 Nov; 12(21):6444-51. PubMed ID: 17085658
[TBL] [Abstract][Full Text] [Related]
13. L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma.
Tsutsumi S; Morohashi S; Kudo Y; Akasaka H; Ogasawara H; Ono M; Takasugi K; Ishido K; Hakamada K; Kijima H
J Surg Oncol; 2011 Jun; 103(7):669-73. PubMed ID: 21360711
[TBL] [Abstract][Full Text] [Related]
14. Galectin-3 expression is a potent prognostic marker in colorectal cancer.
Endo K; Kohnoe S; Tsujita E; Watanabe A; Nakashima H; Baba H; Maehara Y
Anticancer Res; 2005; 25(4):3117-21. PubMed ID: 16080575
[TBL] [Abstract][Full Text] [Related]
15. Galectin-3 expression in colorectal cancer: relation to invasion and metastasis.
Tsuboi K; Shimura T; Masuda N; Ide M; Tsutsumi S; Yamaguchi S; Asao T; Kuwano H
Anticancer Res; 2007; 27(4B):2289-96. PubMed ID: 17695516
[TBL] [Abstract][Full Text] [Related]
16. Increased serum 90K and Galectin-3 expression are associated with advanced stage and a worse prognosis in diffuse large B-cell lymphomas.
Kim SJ; Lee SJ; Sung HJ; Choi IK; Choi CW; Kim BS; Kim JS; Yu W; Hwang HS; Kim IS
Acta Haematol; 2008; 120(4):211-6. PubMed ID: 19153476
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor-gamma and retinoid X receptor-alpha expression in pancreatic ductal adenocarcinoma: association with clinicopathological parameters, tumor proliferative capacity, and patients' survival.
Giaginis C; Katsamangou E; Tsourouflis G; Zizi-Serbetzoglou D; Kouraklis G; Theocharis S
Med Sci Monit; 2009 May; 15(5):BR148-56. PubMed ID: 19396032
[TBL] [Abstract][Full Text] [Related]
18. Galectin-9, a novel prognostic factor with antimetastatic potential in breast cancer.
Yamauchi A; Kontani K; Kihara M; Nishi N; Yokomise H; Hirashima M
Breast J; 2006; 12(5 Suppl 2):S196-200. PubMed ID: 16959001
[TBL] [Abstract][Full Text] [Related]
19. Intraductal papillary mucinous neoplasms of the pancreas: an analysis of protein expression and clinical features.
Nishikawa N; Kimura Y; Okita K; Zembutsu H; Furuhata T; Katsuramaki T; Kimura S; Asanuma H; Hirata K
J Hepatobiliary Pancreat Surg; 2006; 13(4):327-35. PubMed ID: 16858545
[TBL] [Abstract][Full Text] [Related]
20. CD74 is a novel prognostic factor for patients with pancreatic cancer receiving multimodal therapy.
Nagata S; Jin YF; Yoshizato K; Tomoeda M; Song M; Iizuka N; Kitamura M; Takahashi H; Eguchi H; Ohigashi H; Ishikawa O; Tomita Y
Ann Surg Oncol; 2009 Sep; 16(9):2531-8. PubMed ID: 19499276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
